Carregant...

Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis

BACKGROUND: In a 72-week, randomised controlled trial of obeticholic acid (OCA) in non-alcoholic steatohepatitis (NASH), OCA was superior to placebo in improving serum ALT levels and liver histology. OCA therapy also reduced weight. AIMS: Because weight loss by itself can improve histology, to perfo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Aliment Pharmacol Ther
Autors principals: Hameed, B., Terrault, N. A., Gill, R. M., Loomba, R., Chalasani, N., Hoofnagle, J. H., Van Natta, M. L.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931362/
https://ncbi.nlm.nih.gov/pubmed/29333665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14492
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!